CONNECTA Therapeutics Secures €3.1M for Fragile X Program
BARCELONA, Spain — September 10, 2026 CONNECTA Therapeutics announced the closing of a €3.1 million financing led by new...
neurodevelopmental disorder
Advertisement
Acadia Pharmaceuticals’ DAYBU Approved in EU for Rett Syndrome
SAN DIEGO, U.S, Aug 28, 2026 Acadia Pharmaceuticals Inc. announced that the European Commission (EC) has granted marketing authorization...
Waters Strengthens Clinical Diagnostics with Xevo XR Innovation
MILFORD, Mass., July 27, 2026 Waters Corporation has introduced the Xevo™ TQ Absolute XR IVD Mass Spectrometer, expanding its...
BioMarin Partners n-Lorem on First ReNU Syndrome Therapy
SAN RAFAEL, Calif. & SAN DIEGO, July 27, 2026 BioMarin Pharmaceutical Inc. and the n-Lorem Foundation have announced a...
Otsuka’s SIMTRIYO® Becomes First Approved NDSRI for ADHD
PRINCETON, N.J., July 27, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) have announced...
Advertisements
Acadia Expands DAYBUE STIX Access for Rett Syndrome
San Diego, California, USA, April 7, 2026 Broad U.S. Availability Expands Patient Access In a major advancement for rare...
Advertisement
